Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Open access
Karagiannis, Thomas, Avgerinos, Ioannis, Liakos, Aris, Del Prato, Stefano, Matthews, David R., Tsapas, Apostolos, Bekiari, Eleni · 2022 · Diabetologia

Abstract

Aims/hypothesis: Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval. Individual trials have assessed the clinical profile of tirzepatide vs different comparators. We conducted a systematic review and meta-analysis to assess the efficacy and safety of tirzepatide for type 2 diabetes. Methods: We searched PubMed, Embase, Cochrane and ClinicalTrials.gov up until 27 October 2021 for randomised controlled trials with a duration of at least 12 weeks that compared once-weekly tirzepatide 5, 10 or 15 mg with placebo or other glucose-lowering drugs in adults with type 2 diabetes irrespective of their background glucose-lowering treatment. The primary outcome was change in HbA 1c from baseline. Secondary efficacy outcomes included change in body weight, proportion of individuals reaching the HbA 1c target of <53 mmol/mol (<7.0%), ≤48 mmol/mol (≤6.5%) or <39 mmol/mol (<5.7%), and proportion of individuals with body weight loss of at least 5%, 10% or 15%. Safety outcomes included hypoglycaemia, gastrointestinal adverse events, treatment discontinuation due to adverse events, serious adverse events, and mortality. We used version 2 of the Cochrane risk-of-bias tool for randomised trials to assess risk of bias for the primary outcome. Results: Seven trials (6609 participants) were included. A dose-dependent superiority in lowering HbA 1c was evident with all three tirzepatide doses vs all comparators, with mean differences ranging from −17.71 mmol/mol (−1.62%) to −22.35 mmol/mol (−2.06%) vs placebo, −3.22 mmol/mol (−0.29%) to −10.06 mmol/mol (−0.92%) vs GLP-1 RAs, and −7.66 mmol/mol (−0.70%) to −12.02 mmol/mol (−1.09%) vs basal insulin regimens. Tirzepatide was more efficacious in reducing body weight; reductions vs GLP-1 RAs ranged from 1.68 kg with tirzepatide 5 mg to 7.16 kg with tirzepatide 15 mg. Incidence of hypoglycaemia with tirzepatide was similar vs placebo and lower vs basal insulin. Nausea was more frequent with tirzepatide vs placebo, especially with tirzepatide 15 mg (OR 5.60 [95% CI 3.12, 10.06]), associated with higher incidence of vomiting (OR 5.50 [95% CI 2.40, 12.59]) and diarrhoea (OR 3.31 [95% CI 1.40, 7.85]). Odds of gastrointestinal events were similar between tirzepatide and GLP-1 RAs, except for diarrhoea with tirzepatide 10 mg (OR 1.51 [95% CI 1.07, 2.15]). Tirzepatide 15 mg led to higher discontinuation rate of study medication due to adverse events regardless of comparator, while all tirzepatide doses were safe in terms of serious adverse events and mortality. Conclusions/interpretation: A dose-dependent superiority on glycaemic efficacy and body weight reduction was evident with tirzepatide vs placebo, GLP-1 RAs and basal insulin. Tirzepatide did not increase the odds of hypoglycaemia but was associated with increased incidence of gastrointestinal adverse events. Study limitations include presence of statistical heterogeneity in the meta-analyses for change in HbA 1c and body weight, assessment of risk of bias solely for the primary outcome, and generalisation of findings mainly to individuals who are overweight or obese and already on metformin-based background therapy. PROSPERO registration no. CRD42021283449. Graphical abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-022-05715-4

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow chart for the identification, inclusion and exclusion of studies
Fig. 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow chart for the identification, inclusion and exclusion of studiesCC BY · PubMed Central
Fig. 2 Meta-analysis results for tirzepatide vs placebo (a) and vs GLP1-RAs (b) for change in HbA1c (mmol/mol). MD, mean difference
Fig. 2 Meta-analysis results for tirzepatide vs placebo (a) and vs GLP1-RAs (b) for change in HbA1c (mmol/mol). MD, mean differenceCC BY · PubMed Central
Fig. 3 Meta-analysis results for tirzepatide vs placebo (a) and vs GLP1-RAs (b) for change in body weight (kg). MD, mean difference
Fig. 3 Meta-analysis results for tirzepatide vs placebo (a) and vs GLP1-RAs (b) for change in body weight (kg). MD, mean differenceCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 292

Metadata

Authors
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E.
Affiliations
  • Aristotle University of Thessaloniki (GR)
  • Churchill Hospital (GB)
Corresponding author
Karagiannis, Thomas
Venue
Diabetologia
Published
2022-05-17
Volume
65
Issue
8
Pages
1251-1261
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4280579438
Cited by
272
References
30
Citations by year
2026: 32 · 2025: 66 · 2024: 81 · 2023: 72 · 2022: 21
FWCI
8.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
type 2 diabetes, GIP/GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide, GLP-1 receptor agonists, HbA1c, HbA1c reduction, weight loss, hypoglycemia, gastrointestinal adverse effects, drug safety, dose-response relationship, basal insulin, antidiabetic drugs
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diarrhea, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Treatment Outcome, Glucagon-Like Peptide 1, Insulins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s00125-022-05715-4
The paper
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022). Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. https://doi.org/10.1007/s00125-022-05715-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.